$NMTC | #NeuroOne to Compete with Elon Musk's Neuralink
The Float Is Razor Thin Chart Is Trending Bullish Substantial Market Opportunity Strong And Growing Patent Portfolio Plans To Uplist Expected FDA 510(k) Submission For 2nd Product Majority of NeuroOne’s products expect US FDA 501 process. Comapny Profile NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, essential tremors and other related neurological disorders that may improve patient outcomes and reduce procedural costs.
Why NeuroOne? NeuroOne (OTCQB:NMTC) is a next generation electrode technology company specializing in development and commercialization of hi-definition thin film electrodes for the diagnosis and treatment of various neurological conditions such as epilepsy, Parkinson’s Disease and chronic pain due to failed back surgery syndrome First FDA 510(k) clearance for cortical electrode product family December 2019 Potential ability to perform recording, ablation and stimulation with the same electrode Minimally invasive flexible patented technology leverages printed circuit technology We expect our technology could reduce manufacturing costs, procedural costs and improve patient outcomes Mayo Clinic assisted in the development process, successfully used devices in humans as part of a research protocol and currently maintains an ownership position in the Company. WARF (University of Madison-Wisconsin’s Alumni Research Foundation) also assisted in development) Well positioned electrode technology has strong potential for future use in DBS (deep brain stimulation) spinal cord stimulation and artificial intelligence applications, which may play an important future role in treating patients with more complex neurological issues Experienced Management Team, Board of Directors and two Advisory Boards with highly acclaimed physicians from prestigious institutions Strong and growing patent portfolio(MI tool, drug delivery, spinal cord stim )
The Bottom Line With its low-float and recent announcements, we believe that NMTC is in for a huge day of trading. The Company is in the midst of a major growth period, and we believe it has the potential to double in price from here. Having been granted the regulatory green light to begin bringing its product line to market, Neuro-One’s stock is still ranging within its lows (currently at around $2.00 per share). This shouldn’t come as a surprise, as the emerging healthcare space is often too specialized a sub-industry for most mainstream investors to monitor let alone understand. But for the few who can grasp both the relevance and growth potential of Neuro-One’s product line, the company offers early investors an opportunity to get in on a much-needed medical product that, to date, sees neither comparable solutions nor formidable competition. Traders looking for a company that is committed to growth, and with plenty of upside should add NMTC to the top of their watchlist immediately..By Viewing this Content, you Agree that you Have Read and are in Full Understanding of both our Disclaimer & Privacy Policy(*Remember to use a Stop-Loss Order to protect your gains, as well as limit possible losses.) Best Regards
Official InvestorsHub (IHUB) Profile for #TFMG | #theFinancialMarketingGroup:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.